肥胖治疗的一场革命。 - Suppr | 超能文献

相似文献

1

A revolution in obesity treatment.肥胖治疗的一场革命。

Nat Med. 2023 Oct;29(10):2406-2408. doi: 10.1038/s41591-023-02538-7.

2

Dr. Atkins' diet revolution: a review.阿特金斯博士的饮食革命：一篇综述。

Va Med Mon (1918). 1974 May;101(5):383-5.

3

A critique of low-carbohydrate ketogenic weight reduction regimens. A review of Dr. Atkins' diet revolution.对低碳水化合物生酮减肥方案的批判。阿特金斯博士《饮食革命》述评。

JAMA. 1973 Jun 4;224(10):1415-9. doi: 10.1001/jama.1973.03220240055018.

4

[Comments on obesity; Brillat-Savarin and the treatment of obesity].[关于肥胖症的评论；布里亚-萨瓦兰与肥胖症治疗]

Rev Iber Endocrinol. 1956 May-Jun;3(15):331-6.

5

Advancing the revolution in the behavioral treatment of obesity.推动肥胖行为治疗的革命。

Obesity (Silver Spring). 2016 Oct;24(10):2029-30. doi: 10.1002/oby.21641.

6

[Obesity: Progress in diagnosis and treatment; Topics, II. Progress in treatment; 1. Behavioral therapy for obesity].[肥胖症：诊断与治疗进展；主题，二、治疗进展；1. 肥胖症的行为疗法]

Nihon Naika Gakkai Zasshi. 2011 Apr 10;100(4):917-27. doi: 10.2169/naika.100.917.

7

[Treatment of android obesity and its complications].[男性型肥胖症及其并发症的治疗]

Alger Medicale. 1956 Feb;60(2):91-9.

8

A second vaccine revolution for the new epidemics of the 21st century.21世纪新流行病的第二次疫苗革命。

Drug Discov Today. 2006 Nov;11(21-22):1028-33. doi: 10.1016/j.drudis.2006.09.006. Epub 2006 Sep 26.

9

Operative treatment of abdominal obesity, especially pendulous abdomen.腹部肥胖症的手术治疗，尤其是悬垂腹。

Br J Plast Surg. 1949 Jan;1(4):274-83.

10

Obesity treatment: the high cost of false hope.肥胖症治疗：虚假希望的高昂代价。

J Am Diet Assoc. 1991 Oct;91(10):1248-51.

引用本文的文献

1

From BMI to Disease Diagnosis: What Clinical and Pre-clinical Obesity Mean for Surgeons.从体重指数到疾病诊断：临床和临床前肥胖对外科医生的意义。

Obes Surg. 2025 Aug 13. doi: 10.1007/s11695-025-08159-y.

2

Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition.肥胖患者实现持久疗效的新证据和潜在途径：营养与微生物群对身体成分的共同影响

Rev Endocr Metab Disord. 2025 Jul 2. doi: 10.1007/s11154-025-09977-2.

3

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes.

本文引用的文献

1

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Retatrutide，一种胰高血糖素样肽-1（GLP-1）和胰高血糖素受体双重激动剂，用于治疗 2 型糖尿病患者：一项在美国进行的随机、双盲、安慰剂和阳性对照、平行组、2 期临床试验。

Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.

2

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.在 2 型糖尿病成人中，每日口服一次司美格鲁肽 25mg 和 50mg 与 14mg 相比的疗效和安全性（PIONEER PLUS）：一项多中心、随机、3b 期临床试验。

Lancet. 2023 Aug 26;402(10403):693-704. doi: 10.1016/S0140-6736(23)01127-3. Epub 2023 Jun 26.

3